SavedAdd your journal

Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2020 / Cilt: 54 - Sayı: 4

The Association between Chronic Use of Renin–AngiotensinAldosterone System Blockers and in-Hospital Adverse Events among COVID-19 Patients with Hypertension

Gökhan ÇETİNKAL
Betül BALABAN KOÇAŞ
Özgür Selim SER
Hakan KİLCİ
Süleyman YILDIZ
Safiye Nur ÇELEBİ
Yıldız VERDİ
Mustafa ALTINAY
Kadriye Orta KILIÇKESMEZ
Pages
399–404
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The logistic regression multivariateanalysis showed that age, neutrophil-lymphocyte ratio, procalcitonin and ferritin levels were independent predictors of in-hospitalmortality.Conclusion: Our results suggest that chronic use of ACEI/ARBs did not increase in-hospital adverse outcomes of hypertensivepatients hospitalized with COVID-19.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The effects of chronic renin–angiotensin–aldosterone system (RAAS) blockers usage on adverse outcomes and disease severity remain uncertain in COVID-19 patients with hypertension.
📊
Key Findings & Data:In this study, we aimed to determine the relationshipbetween chronic use of RAAS inhibitors and in-hospital adverse events among hypertensive patients hospitalized with COVID-19.Methods: In this retrospective single-center study, we enrolled 349 consecutive hypertensive patients diagnosed with COVID-19infection.
💡
Conclusion & Impact:The logistic regression multivariateanalysis showed that age, neutrophil-lymphocyte ratio, procalcitonin and ferritin levels were independent predictors of in-hospitalmortality.Conclusion: Our results suggest that chronic use of ACEI/ARBs did not increase in-hospital adverse outcomes of hypertensivepatients hospitalized with COVID-19.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: The effects of chronic renin–angiotensin–aldosterone system (RAAS) blockers usage on adverse outcomes and disease severity remain uncertain in COVID-19 patients with hypertension. In this study, we aimed to determine the relationshipbetween chronic use of RAAS inhibitors and in-hospital adverse events among hypertensive patients hospitalized with COVID-19.Methods: In this retrospective single-center study, we enrolled 349 consecutive hypertensive patients diagnosed with COVID-19infection. All patients were chronically on angiotensin-converting enzyme inhibitors (ACEI)/ angiotensin II receptor blockers (ARB)or other antihypertensive therapies before hospital admission. Adverse clinical events were defined as in-hospital mortality, admission to intensive care unit, need for high-flow oxygen and intubation.Results: Patients were categorized into two groups according to the type of antihypertensive therapy. (ACEI/ARBs users, N=201;ACEI/ARB nonusers, N=148) There was no statistically significant difference between ACEI/ARBs users and ACEI/ARBs nonusersconcerning adverse clinical events, such as in-hospital mortality (29 (14.4%) vs. 20 (13.5%), p=0.81), ICU admission (45(22.4%)vs. 27 (18.2%), p=0.34), need for high-flow oxygen (97 (48.3%) vs. 68 (45.9%), p=0.67) and need for intubation (32(15.9%) vs.23(15.5%), p=0.92), respectively. Also, the severity of infection did not differ among groups. The logistic regression multivariateanalysis showed that age, neutrophil-lymphocyte ratio, procalcitonin and ferritin levels were independent predictors of in-hospitalmortality.Conclusion: Our results suggest that chronic use of ACEI/ARBs did not increase in-hospital adverse outcomes of hypertensivepatients hospitalized with COVID-19. Although the recent data are contradictory, chronic ACEI/ARB therapy is not recommendedto be discontinued in hypertensive patients during their hospitalization for COVID-19.

🔖

Cite This Article

ÇETİNKAL, G., KOÇAŞ, B. B., SER, Ö. S., KİLCİ, H., YILDIZ, S., ÇELEBİ, S. N., VERDİ, Y., ALTINAY, M., KILIÇKESMEZ, K. O. (2020). The Association between Chronic Use of Renin–AngiotensinAldosterone System Blockers and in-Hospital Adverse Events among COVID-19 Patients with Hypertension. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 54 - Sayı: 4, 399–404. https://ajindex.com/articles/363686

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Chen R, Liang W, Jiang M, Guan W, Zhan C, Wang T, et al; Medical Treatment Expert Group for COVID-19. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. Chest 2020;158:97–105
  2. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020;369:m1966
  3. Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res 2020;126:1671–81
  4. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3
  5. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;181:271–80
  6. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirusinduced lung injury. Nat Med 2005;11:875–9
  7. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8:e21
  8. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020;17:259–60
  9. Bavishi C, Maddox TM, Messerli FH. Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiol 2020;5:745–7
  10. WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019. Available at: https://www.who.int/docs/defaultsource/coronaviruse/who-china-joint-mission-on-covid-19-finalreport.pdf. Accessed Oct 20, 2020
  11. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005;111:2605–10
  12. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020;382:1653–9
  13. Selçuk M, Çınar T, Keskin M, Çiçek V, Kılıç Ş, Kenan B, et al. Is the use of ACE inb/ARBs associated w